Unknown

Dataset Information

0

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.


ABSTRACT: In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n = 333) vs. remain on tenofovir disoproxil fumarate (TDF; n = 330), each coformulated with emtricitabine (FTC), while continuing their third agent (boosted protease inhibitor or unboosted third agent). At week 96, 88.6% on FTC/TAF and 89.1% on FTC/TDF had HIV-1 RNA <50 copies per milliliter [adjusted difference -0.5% (95% confidence interval: -5.3 to 4.4%)]. Proteinuria, albuminuria, proximal renal tubular function, and bone mineral density improved after switching to TAF- from TDF-containing regimens. These longer-term data support FTC/TAF as a safe, well-tolerated, and durable nucleotide reverse transcriptase inhibitor backbone.

SUBMITTER: Raffi F 

PROVIDER: S-EPMC5427981 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.

Raffi François F   Orkin Chloe C   Clarke Amanda A   Slama Laurence L   Gallant Joel J   Daar Eric E   Henry Keith K   Santana-Bagur Jorge J   Stein David K DK   Bellos Nicholaos N   Scarsella Anthony A   Yan Mingjin M   Abram Michael E ME   Cheng Andrew A   Rhee Martin S MS  

Journal of acquired immune deficiency syndromes (1999) 20170601 2


In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n = 333) vs. remain on tenofovir disoproxil fumarate (TDF; n = 330), each coformulated with emtricitabine (FTC), while continuing their third agent (boosted protease inhibitor or unboosted third agent). At week 96, 88.6% on FTC/TAF and 89.1% on FTC/TDF had HIV-1 RNA <50 copies per milliliter [adjusted difference -0.5% (95% confidence interval: -5.3 to 4.4%)  ...[more]

Similar Datasets

| S-EPMC6905536 | biostudies-literature
| S-EPMC8282313 | biostudies-literature
| S-EPMC6221083 | biostudies-literature
| S-EPMC8775237 | biostudies-literature
| S-EPMC6954396 | biostudies-literature
| S-EPMC5264242 | biostudies-literature
| S-EPMC6425939 | biostudies-literature
| S-EPMC8496521 | biostudies-literature
| S-EPMC8607928 | biostudies-literature
| S-EPMC7935460 | biostudies-literature